CD137/Nectin-4 bispecific-targeting agent BT748
Term · Oncology and biomedicine · MLC-T-ONC-012366
A synthetic tumor targeted immune cell agonist composed of two bicyclic peptides targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9) linked to a bicyclic peptide targeting the cell adhesion molecule nectin-4 (PVRL4); with potential immunostimulating and antineoplastic activities. Upon administration, CD137/nectin-4 bispecific-targeting agent BT7480 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T lymphocytes, and nectin-4 expressed on tumor cells. The simultaneous binding to nectin-4 and CD137 allows for conditional stimulation of CD137 signaling within the tumor microenvironment (TME) only upon binding to nectin-4 on tumor cells. CD137 activation results in T-cell stimulation and enhances T-lymphocyte-mediated anti-tumor immune response against nectin-4-expressing tumor cells. Nectin-4, a tumor associated antigen (TAA) belonging to the nectin family, is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.
| Identifier | MLC-T-ONC-012366 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | 4-1BB/Nectin-4 bispecific-targeting agent BT7480; Nectin-4/CD137 bispecific-targeting agent BT7480; CD137/Nectin-4 bispecific tumor-targeted immune cell agonist BT7480; CD137/Nectin-4 bispecific TICA BT7480 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012366",
"term": "CD137/Nectin-4 bispecific-targeting agent BT748",
"field": "Oncology and biomedicine",
"definition": "A synthetic tumor targeted immune cell agonist composed of two bicyclic peptides targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9) linked to a bicyclic peptide targeting the cell adhesion molecule nectin-4 (PVRL4); with potential immunostimulating and antineoplastic activities. Upon administration, CD137/nectin-4 bispecific-targeting agent BT7480 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T lymphocytes, and nectin-4 expressed on tumor cells. The simultaneous binding to nectin-4 and CD137 allows for conditional stimulation of CD137 signaling within the tumor microenvironment (TME) only upon binding to nectin-4 on tumor cells. CD137 activation results in T-cell stimulation and enhances T-lymphocyte-mediated anti-tumor immune response against nectin-4-expressing tumor cells. Nectin-4, a tumor associated antigen (TAA) belonging to the nectin family, is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.",
"synonyms": [
"4-1BB/Nectin-4 bispecific-targeting agent BT7480",
"Nectin-4/CD137 bispecific-targeting agent BT7480",
"CD137/Nectin-4 bispecific tumor-targeted immune cell agonist BT7480",
"CD137/Nectin-4 bispecific TICA BT7480"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/cd137-nectin-4-bispecific-targeting-agent-bt748/"
}
Record 4,381 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.